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Background: Term and near-term infants are at high risk of developing brain injury and life-long disability if they
have suffered from severe perinatal asphyxia. We hypothesized that propofol administration to the maternal-fetal
unit can diminish cerebral injury in term and near-term infant fetuses in states of progressive severe asphyxia.
Methods: Forty-four late preterm lambs underwent total umbilical cord occlusion (UCO) or sham treatment in
utero. UCO resulted in global asphyxia and cardiac arrest. After emergency cesarean section under either maternal
propofol or isoflurane anesthesia, the fetuses were resuscitated and subsequently anesthetized the same way as
their mothers.
Results: Asphyctic lambs receiving isoflurane showed a significant increase of total and low-frequency spectral
power in bursts indicating seizure activity and more burst-suppression with a marked increase of interburst interval
length during UCO. Asphyctic lambs receiving propofol showed less EEG changes. Propofol increased levels of
anti-apoptotic B-cell lymphoma-extra large (Bcl-xL) and phosphorylated STAT-3 and reduced the release of cytochrome
c from the mitochondria and the protein levels of activated cysteinyl aspartate-specific protease (caspase)-3, -9, and
N-methyl-d-aspartate (NMDA) receptor.
Conclusions: Improvement of fetal EEG during and after severe asphyxia could be achieved by propofol treatment of
the ovine maternal-fetal unit. The underlying mechanism is probably the reduction of glutamate-induced cytotoxicity
by down-regulation of NMDA receptors and an inhibition of the mitochondrial apoptotic pathway.
Keywords: Asphyxia; Propofol; Preterm; Neuroprotection; Lamb; Neonatal resuscitationBackground
Perinatal asphyxia has been associated with severe neuro-
logical and psychiatric sequelae resulting from injury in
the basal ganglia/thalamus and cerebral cortex [1]. Despite
the fact that therapeutic hypothermia is now standard
care and improved the outcome in term-born infants
after mild and moderate perinatal asphyxia [2], the* Correspondence: matthias.seehase@med.uni-goettingen.de
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in any medium, provided the original work is pincidence of neurological disabilities related to perinatal
brain damage due to severe asphyxia has not decreased
significantly in Western countries over the last decades
[3]. In the clinical setting, after resuscitation of an in-
fant with severe birth asphyxia, the emphasis is on sup-
portive therapy [4]. Brain injury after perinatal asphyxia
often develops with delayed clinical onset, opening a
therapeutic window. It has been shown previously that
apoptosis is the leading feature of cerebral cell loss in
human fetuses suffering from asphyxia-related neonatal
brain injury [5]. Many environmental and therapeutic
agents initiate apoptotic cell death by inducing the re-
lease of cytochrome c from the mitochondria [6], whichan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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9, an initiator caspase, and finally recruits the effector
caspase-3. This initiates the caspase cascade that is re-
sponsible for the execution phase of apoptosis [6]. This
pathway is controlled by B-cell lymphoma-extra large
(Bcl-xL) and phosphorylated signal transducer and acti-
vator of transcription-3 (pSTAT-3) [7].
Currently, the only clinically established approach to re-
duce cell loss in asphyxia is moderate hypothermia [2]. In
adult patients undergoing surgical procedures and clinical
situations where protecting the CNS is a priority (cardio-
pulmonary bypass, subarachnoid hemorrhage, stroke, and
postcardiac arrest resuscitation), the choice of anesthetic
drug is essential [8]. Except for xenon [9], anesthetic agents
have not been tested for their potential to protect the de-
veloping brain. One of the most promising anesthetic
agents in mediating neuroprotection in hypoxic insults in
adults is propofol [10]. Apart from its multiple anesthetic
advantages, the short-acting intravenous anesthetic agent
exerts a number of non-anesthetic effects. Propofol has
proved to be able to reduce glutamate and N-methyl-d-as-
partate (NMDA) receptors responses related to cytotoxicity
in the brain [10]. Further on, it decreased the secretion of
proinflammatory cytokines, impaired neutrophil chemo-
taxis, phagocytosis, and production of reactive oxygen spe-
cies (ROS) [11,12]. This is of importance as it may be a
way to interrupt the neuroinflammatory cascade character-
ized by astrocyte and microglial activation, cytokine re-
lease, and ROS formation following hypoxia.
Based on these considerations, we hypothesized that
propofol may reduce neonatal brain injury resulting from
severe asphyxia and fetal cardiac arrest in utero if propofolTable 1 Numbers of lambs per group, gender, body weight, t
of cord blood
GA control Propofol control
Included fetal lambs 8 11
Female/male 4/4 3 / 8
Body weight [kg] 3.59 ± 0.14 3.57 ± 0.15
Exact time of MABP < 30 mmHg
during UCO [min]
- -




Mean duration of chest
compression [min]
0 0
Adrenalin during CPR: yes/no 0/8 0/11
Total dose of adrenalin [μg/kgBW] 0 0
pH before birth (and UCO) 7.26 ± 0.01 7.26 ± 0.01
pH after birth - 7.10 ± 0.03
pH after 8 h of intensive care - 7.19 ± 0.05
All data are given as absolute values or mean ± SEM. An asterisk (*) means significa
arterial blood pressure; UCO, umbilical cord occlusion; CPR, cardiopulmonary resuscis administered to the maternal-fetal unit already before
birth and continued postnatally.
To this purpose, we established a perinatal global as-
phyxia and resuscitation model in near-term sheep in
which we evaluated brain function by EEG and the immu-
nomodulatory and apoptotic changes by assessing several
brain markers in the asphyxiated offspring of pregnant




The study was approved by the Animal Ethics Research
Committee, Maastricht University, The Netherlands. Texel
ewes were date-mated, and the fetuses were randomized
for umbilical cord occlusion (UCO) and sedation. Observa-
tions were made in 44 late preterm fetal sheep of both gen-
ders at mean (range) gestational age of 133 or 134 days
(term 150 days). Eighteen sheep fetuses were subjected to
total UCO in utero, and 18 fetal sheep served as sham con-
trols (Table 1). In each group, about half of the pregnant
ewes and their offspring were sedated with propofol and
the other ones with isoflurane. Eight lambs were eutha-
nized directly after preterm delivery and served as gesta-
tional age (GA) controls.
Experimental protocol
We used the same experimental protocol as published
previously [12]. In brief, the pregnant ewes were
intubated and general anesthesia was maintained with
isoflurane (1% to 2%) or propofol (25 mg/kg/h)
during the cesarean section. Both anesthesia types wereimes of complete umbilical cord occlusion (UCO), and pH
Propofol asphyxia Isoflurane control Isoflurane asphyxia
10 7 8
6 / 4 4 / 3 2 / 6
3.86 ± 0.15 3.57 ± 0.15 3.51 ± 0.15
2.0 ± 0.0 - 2.0 ± 0.0
10.7 ± 0.3 - 11.3 ± 0.6
9/1 0/7 8/0
9.0 ± 0.3 0 9.0 ± 0.4
10/0 0/7 8/0
29 ± 10 0 32 ± 12
7.26 ± 0.01 7.26 ± 0.01 7.26 ± 0.01
6.91 ± 0.03* 7.07 ± 0.02 6.84 ± 0.01*
7.21 ± 0.08 7.16 ± 0.11 7.06 ± 0.14
nt difference with p < 0.01 versus corresponding control group. MABP, mean
itation.
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kg/min). After a lower midline incision, the fetus was care-
fully extracted through a small incision of the uterus. The
fetus was instrumented with an endotracheal tube and an
arterial catheter in the femoral and umbilical artery and a
venous catheter in the external jugular vein. The umbilical
cord was gently extracted through the incision of the
uterus, and a vascular occluder (OC16HD, 16 mm, IN
VIVO METRIC, Healdsburg, California, USA) was placed
around the umbilical cord. The umbilical cord was oc-
cluded until the mean arterial blood pressure (MABP)
dropped below 30 mmHg. From that time point onwards,
the occlusion was continued for exactly 2 min (Figure 1).
After these 2 min, occlusion was stopped regardless of
whether the lambs suffered from bradycardia only or from
cardiac arrest. After the end of the occlusion, the lambs
stayed in utero for 20 s experiencing reperfusion. Then,
they were delivered, the umbilical cord was cut, and resus-
citation was started while the fetus was brought to an open,
heated incubator (IW930 Series CosyCot™ Infant Warmer,
Fisher & Paykel Healthcare). The incubator maintained the
lamb’s body temperature of 38.5°C. When the lambs were
delivered and when their umbilical cord was cut, they wereFigure 1 Study design and time course of experiments. Lambs were b
group were euthanized and their offspring was delivered by cesarean secti
underwent the cesarean section while being sedated with the same anesth
exposed to an average time of total umbilical cord occlusion (UCO) of 11 m
exactly 2 min. This protocol always led to severe bradycardia (HR < 30/min)initially ventilated with a resuscitator bag via the endo-
tracheal tube with room air (60/min). Heart massage was
started with around 120 compressions per minute. The
fetus was brought to the incubator with one medical oper-
ator doing the heart massage while the other one was ven-
tilating the lamb. After arrival at the incubator, the lamb
was connected to a ventilator Servo 900C (Siemens-Elema,
Solna, Sweden), put into plastic foil to prevent cooling ef-
fects, and adrenaline was administered via the venous cath-
eter in augmented doses from 30 μg, to 60 μg, to 0.1 mg.
In addition, a volume bolus of ringer lactate of 10 ml/kg
BW was administered after the first shot of adrenaline.
The lambs were administered with pressure-regulated ven-
tilation using a ventilator with initial settings as follows:
FiO2 = 1, positive end-expiratory pressure, 5 cmH20, peak
inspiratory pressure 30 cmH20, frequency 60/min, and I:E
1:2. Thereafter, inspiratory pressure was adjusted to achieve
a targeted volume of 3.0 L/min and a PaCO2 of 35 to
45 mm Hg. The ventilation and sedation was continued
for 8 h after delivery. The sedation was maintained either
with isoflurane (0.5% to 1.0%) or propofol (1 to 3 mg/kg/h)
and supplemented with remifentanil (3 μg/kg/min) in both
groups. All cord-occluded lambs developed a spontaneousorn at 89% of gestation. The ewes carrying the gestational age control
on and subsequently euthanized. The ewes of the other groups
etic as their offspring later on intensive care unit. Two groups were
in. The cutoff for the occlusion was a MABP below 30 mmHg for
or even cardiac arrest.
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10 min after starting resuscitation with the exception of
two lambs, which were excluded from the study.
The 18 sham-treated fetuses were prepared in utero
with the same catheters and endotracheal intubation as
the study groups. Eleven minutes (mean time of occlusion
in study group as determined in advance in pilot experi-
ments) after the end of the instrumentation, they were
delivered, weighed, sedated, and connected to pressure-
controlled ventilation (see above).
At 8 h after delivery, the lambs were euthanized by an i.v.
injection of T61® (Veterinaria AG, Zürich, Switzerland).
The pregnant ewes carrying the GA control lambs
were euthanized using an injection of T61®. Their off-
spring was delivered surgically immediately thereafter
and were also directly euthanized using an injection of
T61® without any previous catheterization or ventilation
before.
After euthanasia, the brains of all lambs were immedi-
ately removed from the skull and separated at the mid-
line. From one hemisphere, tissue samples were taken
and snap-frozen in liquid nitrogen. Tissue was subse-
quently stored at −80°C.
Electroencephalogram
Two bipolar pairs of electroencephalogram (EEG) silver
ball electrodes (AS633-5SSF, Cooner wire Co., Chatsworth,
CA, USA) were placed subcutaneously over the left and
right parasagittal parietal cortex (5 and 15 mm anterior to
bregma and 10 mm lateral), with a reference electrode
placed over the occiput.
The EEG signal was sampled at 250 Hz and stored on
hard-disk for off-line analysis. Data were filtered using a
0.5-Hz high-pass and 30-Hz low-pass fourth-order But-
terworth filter. EEG signal with an amplitude >1,000 μV
was considered an artifact and removed from analysis
(1% of data). After filtering, background analysis of the
EEG was performed using an amplitude- and time-
threshold-based algorithm [13,14]. Burst activity was
defined as an epoch with an amplitude >15 μV and a
duration of >1 s in both channels. Interburst intervals
were defined as epochs with an amplitude <15 μV and a
duration >3 s in both channels [13]. Segments not meet-
ing above criteria were classified as undefined [13].
Using this approach, the algorithm detected burst, five
interburst interval, and undefined segments in 47%, 28%,
and 25% of cases, respectively.
Subsequently, spectral analysis was performed using
Matlab® (The MathWorks, Massachusetts, USA). Data
was divided into half-overlapping 4-s segments around
the center of each burst. Each segment was multiplied
by a Hamming window before Fourier transform. The fre-
quency spectrum was determined for each segment and
was divided in δ1 (0.5 to 1 Hz), δ2 (1 to 4 Hz), θ (4 to8 Hz), α (8 to 13 Hz), and β (13 to 30 Hz) band. Like-
wise, spectral analysis was performed for the interburst
intervals.
Three aspects of the transformed signal were calculated:
(a) absolute power (defined as the integral of all powers
within the frequency band 0.5 to 30 Hz, expressed in
μV2), (b) relative power (defined as the ratio of absolute
band power to total power of all bands, expressed in per-
centage), (c) spectral edge frequency (SEF defined as the
frequency that delimits 90% of the power between 0.5 and
30 Hz). Finally, the obtained parameters were averaged
over the left and right channel to obtain median burst fre-
quency parameters per measurement.
In addition, the raw EEG signal was converted in an
amplitude-integrated EEG (aEEG) using the software of the
NicoletOne™ device (Viasys Healthcare, Conshohocken,
PA, USA). The aEEG is a technique in which the EEG
signal is expressed in a simplified and time-compressed
manner [15]. In the neonatal intensive care unit (NICU),
the aEEG has shown to be a very useful tool for long-term
bed-side monitoring of neonatal seizures and background
patterns [16].
Western blotting
Western blots were performed as described previously
[12,17]. Briefly, the whole frozen frontal cortex was ho-
mogenized in ice-cold RIPA buffer (R0278-50ML, Sigma-
Aldrich Corp., St. Louis, MO, USA) containing Halt
Protease and Phosphatase Inhibitor Cocktail, EDTA-free
(100×) (Thermo Fisher Scientific Inc., Rockford, IL 61105
USA). The samples were then centrifuged at 500×g for
20 min at 4°C to remove cellular debris. Protein content
in the supernatant was determined using the Micro BCA
Protein Assay Kit (Thermo Fisher Scientific) with BSA as
the standard.
The following dilutions for antibodies were used:
1:1,000 for monoclonal anti-β-actin clone AC-1 (Sigma-
Aldrich Catalog Number A5441), anti-cleaved-caspase-3
(Asp175) (Cell Signaling Technology, Inc., Danvers, MA,
USA), anti-cleaved-caspase-9 (Novus Biologicals, Littleton
CO, USA), anti-Bcl-xL (Cell Signaling Technology, Inc.,
Danvers, MA, USA), anti-phospho-Akt (Cell Signaling
Technology, Inc., Danvers, MA, USA), anti-pSTAT-3 (Cell
Signaling Technology, Inc., Danvers, MA, USA), and
anti-NMDA receptor (Cell Signaling Technology, Inc.,
Danvers, MA, USA). As secondary antibody IRDye® 680
conjugated goat (polyclonal) anti-rabbit IgG, IRDye® 800
conjugated goat (polyclonal) anti-rabbit IgG, IRDye® 680
conjugated goat (polyclonal) anti-mouse IgG, and IRDye®
800 conjugated goat (polyclonal) anti-mouse IgG (LI-
COR, Lincoln, Nebraska, USA) were used in a dilution
of 1:6,000. The blots were analyzed using the LICOR
Odyssey Infrared Imaging System, and the signals of
the target proteins were normalized to the signal of β-
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were acquired using Adobe Photoshop CS6 software.Cytochrome-c-releasing apoptosis assay kit
Cytochrome c release was determined using the cyto-
chrome-c-releasing apoptosis assay kit (BioVision,
Mountain View, CA, USA) according to the manu-
facturer’s protocol.Lipid peroxidation assay
For brain tissue analysis, we used the ALdetect (MDA-
Specific) Lipid Peroxidation Assay Kit (ALdetect (MDA-
Specific) Lipid Peroxidation Assay Kit BML-AK-171,
Enzo Life Sciences International, Inc., Plymouth Meet-
ing, PA, USA) according to the manufacturer’s manual.Data analysis
Data with a normal distribution are expressed as a mean ±
SEM; otherwise, data are expressed as a median and
interquartile range (IQR). Physiological variables were
analyzed using two-way ANOVA. All other data were
analyzed by the Mann-Whitney-Wilcoxon test. A
p value <0.05 was considered significant. All statistical
analyses were performed using the statistical software
GraphPad Prism 5.0.Results
The lambs had similar gestational ages of 133.7 ±
0.16 days and similar birth weights of 3.6 ± 0.1 kg. All
animals developed a severe bradycardia with a frequency
of <30/min or a cardiac arrest upon reperfusion. Gender
distribution, body weights, and pH and resuscitation de-
tails are given in Table 1. The temperature of all lambs
was kept during the whole experiment between 38.0°C
and 38.5°C. Heart rate and blood pressure did not differ
between groups as published previously [12].Figure 2 Bilateral amplitude-integrated EEG before, during, and after
The y-axis shows the amplitude of the signal and is displayed semi-logarith
(left) represents the onset of occlusion. Before occlusion, the lower margin
decreased to values <10 μV. After occlusion (double arrow), the lower margEEG
Baseline before UCO
Figure 2 illustrates the aEEG trace before, during, and
after the UCO. During baseline condition, the lower
margin amplitude is >10 μV and the upper margin amp-
litude is <25 μV, consistent with a normal background
pattern of the brain. During baseline conditions, the me-
dian bursts per minute, the median total spectral power,
the relative spectral power estimates, and the median
SEF values were not different between the four experi-
mental groups (Figure 3).
Changes of burst activity
During UCO, the aEEG pattern rapidly changed with
upper margin amplitude values <10 μV, consistent with a
low-voltage pattern (Figure 2). In isoflurane-treated
lambs, we observed a 60% decrease in burst per minute
during UCO, whereas in propofol-treated lambs a much
smaller change of 20% was observed. In the post-UCO
phase, we observed significantly more burst activity in
the isoflurane lambs than in the propofol-treated lambs
(median burst/minute 4.8 vs. 1.6, p < 0.05) (Figure 3A).
Burst total spectral power during UCO increased more
in isoflurane-treated lambs than in propofol-treated
lambs (Figure 3B). Of the relative spectral power mea-
sures, δ1 and δ2 were particularly responsible for the in-
crease of burst spectral power in isoflurane-treated
lambs (Figure 3C). The increase of burst spectral power
and relative delta activity was associated with character-
istic repetitive patterns of sharp waves of the raw EEG,
indicating seizure activity (Figure 4).
We observed no significant change in SEF during UCO
or postnatally between isoflurane- and propofol-treated
lambs.
Changes of interburst interval
We found a significant increase in interburst interval
length during UCO, which was significantly greater inocclusion of the umbilical cord. The x-axis shows time in minutes.
mic: linear 0 to 10 μV and logarithmic 10 to 100 μV. The vertical arrow
amplitude is 20 to 25 μV. Within 1 min, the lower margin amplitude
in amplitude increased to pre-occlusion values.
Figure 3 EEG analysis. Pre- and postnatal EEG of control groups and EEG before, during, and after UCO in asphyxia groups. Depicted are (A) the
median burst per minute, (B) the median total spectral power, (C) the relative spectral power for δ1, and (D) the interburst interval length as
median and interquartile range. Significant differences (p < 0.05) are marked by (*). UCO, umbilical cord occlusion; IBI, interburst interval.
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In the propofol control group, the level of N-methyl-d-as-
partate-receptor (NMDA-R) decreased to 31.5% ± 7.8%
(p < 0.02) compared to the GA control group (Figure 5A).
After prenatal asphyxia, NMDA-R levels decreased in pro-
pofol-treated lambs to 24.6% ± 6.6% (p = 0.04) comparedFigure 4 EEG during the postocclusion phase. A 15-min epoch of ampl
time in minutes, y-axis shows the amplitude of the signal and is displayed
a slight increase of the lower margin amplitude and increase of bandwidth
accessory bilateral EEG during the shaded vertical band of the aEEG (bottom,
stick) showing repetitive sharp waves every 2 to 3 s, suggestive of seizure acti
which spectral analysis is performed and shows a relative delta power of 84%to the GA controls and to 46.2% ± 21.7% (p < 0.05) when
compared to the isoflurane asphyxia group.
Phosphorylated signal transducer and activator of
transcription-3 (pSTAT-3, Tyr705)
Protein levels of pSTAT-3 increased in the propofol con-
trol group compared to the GA control group up to
417.8% ± 202.5% (p < 0.05; Figure 5B). In the propofol
asphyxia group, pSTAT-3 increased to 620.8% ± 247.2%
(p < 0.01) compared to the GA control group. After pre-
natal asphyxia, pSTAT-3 increased in isoflurane-treateditude-integrated EEG during the postocclusion phase (top, x-axis shows
semi-logarithmic: linear 0 to 10 μV and logarithmic 10 to 100 μV) shows
, indicated by the shaded dark gray vertical band. Illustration of the
time resolution 1 s/dotted vertical line, sensitivity indicated by vertical
vity in the left hemisphere. The rectangular box indicates the period over
.
Figure 5 Western blot in frontal cortex of fetal brain. Western blot for (A) NMDA receptors, (B) pSTAT-3, (C) Bcl-xL, (D) cytochrome c, (E)
cleaved caspase-9, and (F) cleaved caspase-3 in frontal cortex of fetal brain normalized to β-actin. Levels of the gestational age control group
were set to 1 in all panels. Depicted are mean and SEM. Significant differences (p < 0.05) compared to gestational age control groups are marked
by (*). Significant differences (p < 0.05) between asphyxiated and corresponding non-asphyxiated drug control group are marked by § and significant
differences between asphyxiated propofol and asphyxiated isoflurane treated lambs are marked by ‡. NMDA-R, N-methyl-d-aspartate-receptor; GA,
gestational age; pSTAT-3, phosphorylated signal transducer and activator of transcription-3; Bcl-xL, B-cell lymphoma-extra large; caspase, cysteinyl
aspartate-specific protease.
Seehase et al. Molecular and Cellular Pediatrics  (2015) 2:4 Page 7 of 12lambs to 267.7% ± 45.5% compared to the GA controls
(p < 0.02).
B-cell lymphoma-extra large (Bcl-xL)
In the propofol asphyxia group, Bcl-xL increased to
326.2% ± 94.8% (p = 0.03; Figure 5C) compared to the
GA control group and to 397.0% (p < 0.02) compared to
the isoflurane asphyxia group.
Cytochrome-c-releasing apoptosis assay
In the isoflurane asphyxia group, cytochrome c increased
to 344.7% ± 43.9% compared to the GA control group
(p < 0.01), to 249.4% (p < 0.01) compared to the isoflur-
ane control group, and to 258.4% (p < 0.01) compared to
the propofol asphyxia group (Figure 5D).
Cleaved caspase-9
In the isoflurane asphyxia group, cleaved caspase-9 in-
creased to 273.1% ± 62.1% (p = 0.04) compared to GA, to
325.4% (p < 0.02) compared to the isoflurane controls,
and to 545.7% (p < 0.01) in comparison to the propofol
asphyxia group (Figure 5E).Cleaved caspase-3
In the propofol control group, the protein level of cleaved
caspase-3 decreased to 34.2% ± 9.0% (p < 0.04) compared
to the GA control group (Figure 5F). Cleaved caspase-3
increased by 375.3% in the propofol asphyxia group com-
pared to the propofol controls (p < 0.04). After prenatal
asphyxia, cleaved caspase-3 increased in isoflurane-treated
lambs by 266.7% compared to the isoflurane controls
(p = 0.01), by 261.2% ± 69.9% (p < 0.05) compared to the
GA control group, and up to 203.2% ±54.44% (p < 0.03)
compared to the propofol asphyxia group.
Lipid peroxidation assay
Malondialdehyde (MDA)
Malondialdehyde (MDA) increased by 302.9% in the pro-
pofol asphyxia group compared to the propofol controls
(p < 0.01) and by 256.1% ± 74.4% (p = 0.04) compared to
the GA control group (Figure 6). In the isoflurane control
group, MDA increased by 234.0% ± 57.0% (p = 0.02) com-
pared to the GA control group. After prenatal asphyxia,
MDA increased by 370.4% ± 71.9% (p < 0.01) compared to
the GA control group.
Figure 6 Reactive oxygen species in cerebral fetal cortex.
Malondialdehyde (MDA) levels in cerebral fetal cortex as indication
of lipid peroxidation due to reactive oxygen species (ROS) formation.
Levels of the gestational age control group were set to 1. Depicted
are mean and SEM. Significant differences (p < 0.05) compared to
gestational age control groups are marked by (*). Significant differences
(p< 0.05) between asphyxiated and corresponding not-asphyxiated
drug control group are marked by §. GA, gestational age.
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In this paper, we demonstrate molecular (Figure 7) and
functional changes of the cerebrum of late preterm lambs
in a unique experimental standardized sequence of severe
asphyxia due to complete umbilical cord occlusion in
utero, fetal cardiac arrest, emergency cesarean section,
postnatal resuscitation of the fetus, and intensive care for
the first 8 h after birth. The molecular and functional
changes indicate that medication has the potential to im-
prove fetal cortical function as assessed by amplitude-inte-
grated EEG when the medication is administered already
before birth to the maternal-fetal unit during cesarean sec-
tion and postnatally to the baby on the NICU.
We observed that isoflurane administration to the
maternal-fetal unit before and during the umbilical cord
occlusion resulted in EEG changes with increased burst
spectral power when compared to the propofol-treated
and occluded group. The increased δ1 and δ2 spectral
power burst activity may indicate seizure activity, as this
is characteristically manifested by low-frequency high-
voltage EEG waves [18,19]. This suggests that isoflurane
is associated with more epileptogenic activity than pro-
pofol. Despite sedation, activity of clinical convulsions
was observed in all animals that underwent UCO. Inorder to quantify this potentially biased clinical judg-
ment, we used this standardized analysis. Quantification
of the effects is extremely important in this new ap-
proach since seizures in the neonatal period can be ex-
tremely refractory to therapy [20]. The immature brain
may be more susceptible to the epileptogenic effects of
provoking stimuli, such as hypoxia [20]. Seizures may
alter brain development resulting in epilepsy and neuro-
logic impairment in later life, even in the absence of ob-
vious infarction or other structural injury [20]. In this
context, the smaller increase of (low-frequency) spectral
power during bursts during UCO in our propofol-treated
lambs may be considered beneficial. Moreover, the length
of interburst interval, which is considered to be a predict-
ive EEG marker of neonatal brain injury [21], was less in-
creased during UCO in propofol-treated lambs compared
to isoflurane controls. Hence, less burst-suppression of
the EEG was recorded during propofol sedation. These
changes can partly be explained by propofol, which has
the potential to suppress seizure activity via inhibition of
the NMDA receptor and modulation of the slow calcium
ion channels [22]. A wide range of doses of propofol can
suppress the interictal and ictal activity and abolish the
epileptiform discharges, electrographic seizures, clinical
seizures, and the status epilepticus inducing the burst-sup-
pression pattern [22]. However, data on propofol-induced
EEG changes in epilepsy patients are limited to a few
small-size studies in adults [22], and it is not conclusive as
to whether propofol activates or depresses EEG seizure ac-
tivity in this patient population [23]. Meyer and colleagues
studied the effects of propofol and its continuous infusion
on the EEG in 25 pediatric epilepsy patients which were
sedated to carry out MRI scans. In 16 out of 18 patients
with epilepsy and documented spike-wave patterns prior
to propofol sedation, a suppression of spike-wave patterns
(>90% of baseline seizure activity) was demonstrated. In
addition, no depression or augmentation of EEG ampli-
tudes, a primary occurrence, or an increase in spike-wave
patterns was seen [22,24]. Aside from EEG as a functional
readout, we found that propofol treatment protected the
auditory brainstem response (ABR) threshold as compared
to isoflurane anesthesia in this model as published previ-
ously [25].
Not only does NMDA-receptor-mediated signaling influ-
ence seizure activity and auditory function, but the NMDA
receptor is also involved in hypoxia-reperfusion injury. An
overstimulation of NMDA receptors leads to an excessive
Ca2+-influx and plays a major role in the series of poten-
tially neurotoxic events [26]. One of these events is the
Ca2+ overload of mitochondria, leading to the generation
of ROS. Therefore, inhibition of the NMDA receptor,
or preventing accumulation of ROS, would attenuate
brain damage. A recent study by Sandoval et al. [27]
provided data that even a down-regulation of NMDA
Figure 7 Activation and inhibition of apoptotic pathways in the fetal ovine brain. Propofol reduced expression of NMDA receptors and occurrence
of reactive oxygen species (ROS). In addition, Propofol treatment resulted in activation of pSTAT-3 which inhibited release of cytochrome c
from the mitochondria. Consequently, activation of caspases-9 and -3 was reduced. NMDA-R, N-methyl-d-aspartate-receptor; pSTAT-3, phosphorylated
signal transducer and activator of transcription-3; Bcl-xL, B-cell lymphoma-extra large; caspase, cysteinyl aspartate-specific protease.
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Synaptic NMDA receptors have anti-apoptotic activity,
whereas stimulation of extrasynaptic NMDA receptors
results in a loss of mitochondrial membrane potential
which is an early marker for glutamate-induced neuronal
damage and cell death [28]. Blocking specifically extrasy-
naptic NMDA receptors may effectively prevent neuronal
cell death in conditions associated with ischemia and
glutamate toxicity [28]. The same group showed that
the NMDA receptor NR2A subunits are localized primar-
ily at synapses and promote cell survival whereas NR2B
subunits are contained predominantly in extra-synaptic
NMDA-Rs and promote cell death. Consistent with the
concept that NR2B is involved in cell death, Sandoval
et al. found that the selective pharmacological blockade of
NR2B prevented cell death in cortical cultures [27]. In line
with this, all propofol-sedated lambs in our study showed
a down-regulation of the NMDA receptor subunit NR2B
and better EEG features and less cerebral apoptosis com-
pared with isoflurane-treated animals.
A potential concern in using anesthetic drugs in pre-
term and term newborn infants has come from animal
studies. Anesthetics caused massive induction of apop-
tosis in the developing brain of newborn rodents [29].
However, considering the short gestation in rats (22.5
days) and mice (19.5 days), and their consequently faster
brain development, compared to the relatively long hu-
man gestation (280 days), there may be significant differ-
ences in the effect of a pharmacological intervention
aimed at crucial brain-development-mediating elementssuch as NMDA receptors. In addition, it has to be taken
into account that in contrast to humans important steps
such as white matter myelination occur in rodents after
birth [30]. For these reasons, sheep appear to be an ap-
propriate model since the ovine gestation period is 150
days with prenatal white matter myelination, which is
much closer to the human development [31]. In addition,
sheep have been already extensively used to study the ef-
fects of fetal and perinatal asphyxia [12,25]. Apoptosis is
not only a possible consequence of exposure to anesthetic
drugs but is the leading feature of cerebral cell loss in
asphyxia-related neonatal brain injury [5]. During apop-
tosis, the permeabilization of the mitochondrial outer
membrane allows the release of cytochrome c, which in-
duces caspase activation to orchestrate the death of the
cell. After loosing their transmembrane potential (ΔΨm),
the mitochondria generate ROS which likely contributes
to the dismantling of the cell. Cytochrome c release acti-
vates caspase-9 which in turn initiates the cleavage of
caspase-3. Caspase-3 is the most effective apoptotic regu-
lator because it plays a decisive role in the occurrence of
apoptosis by acting as the effector caspase which deter-
mines the incidence of apoptosis [6]. In our study, cyto-
chrome c release from the mitochondria and subsequent
activation of caspase-9 and caspase-3 was unchanged in
isoflurane-sedated control lambs compared to gestational
age controls suggesting no neurotoxic effect due to isoflur-
ane administration over 8 h. Surprisingly, caspase-3 activa-
tion even decreased in propofol-treated control lambs
compared to gestational age controls and isoflurane-treated
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thereby reduction of apoptosis may be beneficial in neurons
under uncontrolled hypoxic conditions, an exogenously
caused reduction in apoptosis in the healthy developing
brain may be harmful because apoptosis is a vital mechan-
ism in the formation process of neuroplasticity [32].
After UCO, cardiac arrest, successful resuscitation and 8
h of sedation with isoflurane, both caspase-3 and -9 acti-
vation and cytochrome c release increased around three-
fold compared to the normal situation at this time point
in gestation. But after severe asphyxia, there was no in-
crease in cytochrome c release and subsequently, caspase-
3 and -9 showed no activation if lambs were treated with
propofol, suggesting less to no induction of the mitochon-
drial apoptotic pathway.
A possible explanation for our findings was given by Li
et al. [33]. His group provided evidence that propofol
anesthesia during cerebral ischemia led to activation of Bcl-
xL. Bcl-xL inhibits caspase-3 to influence mitochondrial
function without access to the intermembrane space, since
Bcl-xL blocks mitochondrial membrane permeabilization.
Consistent with this, Bcl-xL levels were increased in fetal
brains after propofol anesthesia in our experiment, suggest-
ing that indeed propofol has an inhibitory effect on cas-
pase-3 activation in the late preterm fetus, too. Previous
studies have shown that activation of pSTAT-3 is required
for expression of Bcl-xL [34]. In our experiments, propofol
led to increased phosphorylation of STAT-3 whereas iso-
flurane treatment did not. These data support the concept
that pSTAT-3 and Bcl-xL mediate the cytochrome c/cas-
pase-3 apoptotic process not only in adult but also in cells
of the fetal frontal cortex and that they can be activated by
propofol.
Cytochrome c release and the activation of caspases
feedback on the permeabilized mitochondria increasing
mitochondrial damage and ROS generation [6]. ROS-
mediated lipid peroxidation and DNA damage then ap-
pears to be the final common pathway for neuronal cell
death [26]. The brain of term- and near-term-born infants
seems particularly vulnerable to ROS formation and the
resulting oxidative injury after asphyxia because of imma-
ture scavenging mechanisms and a relative abundance of
iron that acts as a catalyst for the formation of free radi-
cals [6]. One pathway by which propofol exerts its cell-
protective properties in adults is the reduction of the
occurrence of ROS after ischemia [10]. In experimental
settings, it has been shown that activation of caspase-3 re-
sulted in significant ROS production. The increase was
inhibited by Bcl-xL, probably via inhibition of the caspase-
activated permeabilization of the mitochondrial outer
membrane as discussed above. Therefore, it is likely that
the caspase-mediated disruption of respiratory chain com-
plex I and II function contributes to high ROS production
during apoptosis. This would account for the effect ofcaspase inhibition on apoptosis-associated ROS gener-
ation we observed in our experiment. The slightly reduced
lipid peroxidation in our propofol-treated lambs suggest
that the scavenging properties of propofol and its inhibi-
tory effect on caspase-3 cleavage may play a minor role in
mediating protection in the premature brain. Consistent
with this notion, it has been demonstrated in human new-
borns that the degree of lipid peroxidation represents a
valid predictive marker for birth-asphyxia-related morbid-
ity and mortality [35].
One limitation of our study is that we only studied
one time point in gestation, namely late preterm sheep
with a gestational age of 133 days. The fetal brain ma-
tures particularly fast during this final third part of ges-
tation, in both sheep and humans. Observations made at
one time point cannot be easily extrapolated to earlier
or later time points of gestation [36]. Despite the high
similarities between ovine and human brain develop-
ment, one has to be careful in extrapolating our data to
the clinical situation in the hospital. An additional limita-
tion is that we administered anesthesia to the lambs for
8 h whereas term and near-term infants with complica-
tions as birth asphyxia are only getting a full anesthesia
if they undergo surgery, e.g., because of necrotizing en-
terocolitis which is more a problem of preterm infants
whereas severe birth asphyxia is more common in term
and near-term infants [37]. We only examined immedi-
ate occurring changes and injury in brain tissue not
knowing to what extent molecular repair systems would
be capable of coping with the produced injury. We used
EEG recordings to measure how the lambs coped with
the produced brain injury. However, the two-channel
EEG represents a basic surveillance tool for brain activ-
ity which is also used in the clinical scenario but which
is not fully comparable with results gained from a full
EEG [38].
Finally, an often-mentioned concern associated with the
use of propofol in neonates is the occurrence of the pro-
pofol infusion syndrome (PRIS). This is characterized by
hemodynamic abnormalities, lactic acidosis, and rhabdo-
myolysis and carries a mortality of approximately 85%
[39]. As published previously, the propofol-treated lambs
in our study developed no acidosis, no increase in creatine
kinase, and no severe hemodynamic disturbances within 8
h [12]. However, we cannot rule out that a longer use of
propofol or a higher number of treated individuals would
be accompanied with the occurrence of PRIS due to a
relatively high inter-individual variability in propofol
pharmacokinetics in preterm and term neonates [40].
Conclusions
We showed that early propofol administration to the
maternal-fetal unit during severe fetal asphyxia was asso-
ciated with less cerebral dysfunction and less activation of
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preterm lambs. The observed propofol-related EEG im-
provements seemed to be mediated by its ROS-scavenging
properties, an activation of anti-apoptotic agents, such as
pSTAT-3 and Bcl-xL, and its inhibitory influence on the
NMDA pathway. The feasibility of designing a propofol-
based strategy that blocks brain damage without disrupt-
ing normal development in humans will have to be further
evaluated.
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